<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03847571</url>
  </required_header>
  <id_info>
    <org_study_id>Acetazolamide (AZ)</org_study_id>
    <nct_id>NCT03847571</nct_id>
  </id_info>
  <brief_title>Acetazolamide (AZ) for Management of Alkalosis in Bartter Syndrome</brief_title>
  <acronym>AZ</acronym>
  <official_title>Acetazolamide (AZ) for Management of Refractory Hypokalemia Metabolic Alkalosis in Bartter Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective controlled cross over clinical trial, the investigators aim to evaluate
      the efficacy and safety of acetazolamide for the management of metabolic alkalosis in
      children with Bartter syndrome. Urine and blood electrolytes will be measured before and
      after acetazolamide treatment. The primary end point is a change in polyuria, hypokalemia,
      and metabolic alkalosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bartter syndrome is a hereditary salt-loosing tubulopathy caused by several gene mutations
      encoding the sodium reabsorption in the thick ascending limb of loop of Henle, with poor
      response to treatment. The effects of inhibition of proximal tubular reabsorption of
      bicarbonate by acetazolamide have not been previously studied in Batter patients.

      The present study is designed to assess he efficacy and safety of acetazolamide for the
      management of children with Bartter syndrome. The primary end point is change in polyuria,
      hypokalemia, and metabolic alkalosis.

      In this prospective observational crossover clinical trial, patients between ages 1 and 10
      years with clinical diagnosis of Bartter syndrome (hypokalemia, metabolic alkalosis, normal
      blood pressure, elevated urine chloride &gt;20 milliequivalent per liter, high serum aldosterone
      and plasma renin levels) will be enrolled in a 4- week clinical trial. After initial clinical
      and laboratory evaluations, patients will receive acetazolamide 5.0 mg/kg orally as a single
      daily dose and each patient will act as his/her own control. Renal electrolyte and 24-hour
      urine output will be measured at baseline and after the 4 weeks acetazolamide treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic alkalosis</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in serum bicarbonate level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine output</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in 24-hr urine volume</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bartter Syndrome</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <description>Oral administration of acetazolamide 5 mg/kg/day for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Correction of metabolic alkalosis by inhibition of the filtered bicarbonate load reabsorption in the proximal tubules using acetazolamide (AZ)</description>
    <arm_group_label>Acetazolamide</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children between 1 and 10 years of age with failure to thrive, polyuria and unexplained
        hypokalemic metabolic alkalosis will be recruited for this trial.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypokalemia

          -  metabolic alkalosis

          -  normal blood pressure

          -  random urine chloride &gt;20 milliequivalent per liter (mEq/L)

          -  Elevated serum aldosterone and renin levels

        Exclusion Criteria:

          -  Hypertension

          -  History of emesis

          -  Prior use of laxatives

          -  Cystic fibrosis ofpancrease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farahnak Assadi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farahnak Assadi, MD</last_name>
    <phone>3125600477</phone>
    <email>fassadi@rush.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mojgan Mazaheri, MD</last_name>
    <phone>00-98 9123069789</phone>
    <email>mojganmazaheri@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fateme Ghane Sharbaf</name>
      <address>
        <city>Mashhad</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fateme Ghane Sharbaf, MD</last_name>
      <phone>00 98 9153112139</phone>
      <email>ghanesharbaf@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Farahnak Assadi</last_name>
      <phone>3125600477</phone>
      <email>fassadi@rush.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Semnan University of Medical Sciences</name>
      <address>
        <city>Semnan</city>
        <zip>011000</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mojgan Mazaheri, MD</last_name>
      <phone>9123069789</phone>
      <email>mojganmazaheri@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Farahnak Assadi, MD</last_name>
      <phone>3125600477</phone>
      <email>fassadi@rush.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Banafshe Dormansh</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Banafshe Dormanesh, MD</last_name>
      <phone>00 98 9123886725</phone>
      <email>dr.dormansh@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Farahnak Assadi, MD</last_name>
      <phone>3125600477</phone>
      <email>Farahnak_Assadi@rush.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Simin Sadeghi</name>
      <address>
        <city>Zahedan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simin Sadeghi, MD</last_name>
      <phone>00 98 54533295573</phone>
      <email>sisadegh@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Farahnak Assadi, MD</last_name>
      <phone>3125600477</phone>
      <email>fassadi@rush.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 16, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>February 19, 2019</last_update_submitted>
  <last_update_submitted_qc>February 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetazolamide</keyword>
  <keyword>Hypokalemic metabolic alkalosis</keyword>
  <keyword>Bartter syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bartter Syndrome</mesh_term>
    <mesh_term>Alkalosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

